Decision rules for subgroup selection based on a predictive biomarker

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 1, 2014, Pages 188-202

  Krisam, Johannes ^a   Kieser, Meinhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adaptive designs; Sample size calculation; Subgroup selection

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DECISION MAKING; HUMAN; PATIENT SELECTION; PILOT STUDY; PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; BIOLOGICAL MARKERS; HUMANS; MODELS, STATISTICAL; PATIENT SELECTION; POPULATION; SAMPLE SIZE;

EID: 84891809326     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.856018     Document Type: Article

References (12)

1. Addplan, Inc., an Aptiv Solutions Company. (2013). ADDPLAN PE Version 6.0 User Manual, Rev. 3. Cologne, Germany: Aptiv Solutions.
2. Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 28:1445-1463.
3. Carroll, K. J. (2007). Biomarkers in drug development: Friend or foe? A personal reflection gained working within oncology. Pharmaceutical Statistics 6:253-260.
4. Dekker, T. J., Borg, S. T., Hooijer, G. K., Meijer, S. L., Wesseling, J., Boers, J. E., Schuuring, E., Bart, J., van Gorp, J., Mesker, W. E., Kroep, J. R., Smit, V. T., van de Vijver, M. J. (2012). Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Research 14:R93.
5. Friede, T., Parsons, N., Stallard, N. (2012). A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31:4309-4120.
6. Hung, H. M. J., Wang, S. J., O'Neill, R. (2011). Flexible design clinical trial methodology in regulatory applications. Statistics in Medicine 30:1519-1527.
7. Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10:347-356.
8. Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., Jenkins, R. B. (2006). HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology 24:3032-3038.
9. Reddy, J. C., Reimann, J. D., Anderson, S. M., Klein, P. M. (2006). Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clinical Breast Cancer 7:153-157.
10. Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227- 244.
11. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51:358-374.
12. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., Van de Vijver, M. J., Wheeler, T. M., Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25:118-145.